Related Experiment Video
Updated: Jun 26, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Sequential or combination chemotherapy for a patient with mCRC?
1Department of Oncology and Hematology, Martin-Luther-University Halle-Wittenberg, Halle, Germany. dirk.arnold@medizin.uni-halle.de
Abstract:
A 62-year-old male presents with colon cancer that has metastasized to both lobes of the liver. Resection was performed; chemotherapy initially consisted of combination treatment with FOLFIRI or XELIRI plus bevacizumab, with the possibility of changing treatment to either FU/LV or capecitabine, combined with bevacizumab. Although reported data would allow the consideration of a strategy of sequential treatment in this patient, the consulting oncologists treating him have acknowledged the benefit of a strategy employing "inductive" combination chemotherapy plus monoclonal antibodies. Combination chemotherapy offers the potential for longer treatment holidays than is possible with sequential therapy. One of the enduring concepts informing treatment decisions for mCRC is that patients who receive the three mainstays of drug treatment fluorouracil, irinotecan, and oxaliplatin fare better than those who do not.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers
Treatment Resistant Cancers
